<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073125</url>
  </required_header>
  <id_info>
    <org_study_id>M02-428</org_study_id>
    <nct_id>NCT00073125</nct_id>
    <nct_alias>NCT00080704</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma</brief_title>
  <official_title>A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of ABT-510 in&#xD;
      subjects with advanced renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance status</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">103</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-510/Thrombospondin-1 mimetic</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be eligible for study participation if all of the following criteria are&#xD;
        met:&#xD;
&#xD;
          -  The subject is at least 18 years of age.&#xD;
&#xD;
          -  The subject has advanced histologically documented renal cell carcinoma. Advanced&#xD;
             disease is defined as locally recurrent disease or metastatic disease that is not&#xD;
             amendable to curative resection.&#xD;
&#xD;
          -  The subject has not received prior therapy (anti-tumor radiotherapy, immunotherapy,&#xD;
             chemotherapy, or investigational therapy) for metastatic renal cell carcinoma other&#xD;
             than excision of primary tumor where appropriate. Local radiation for supportive&#xD;
             reasons will be allowed; however, not within 28 days from Study Day 1.&#xD;
&#xD;
          -  The subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1&#xD;
&#xD;
          -  The subject is able to self-administer or has a caregiver who can reliably administer&#xD;
             subcutaneous injections.&#xD;
&#xD;
          -  The subject must have adequate bone marrow, renal, and hepatic function as follows:&#xD;
&#xD;
               -  Bone Marrow: White blood cell count (WBC) ≥ 3,000/mm3 (3.0 X 109/L); Platelets ≥&#xD;
                  100,000/mm3 (100 X 109/L); Hemoglobin ≥ 9.0 g/dL (1.4 mmol/L)&#xD;
&#xD;
               -  Renal function: serum creatinine ≤ 2.0 mg/dL (0.81 mmol/L)&#xD;
&#xD;
               -  Hepatic function: AST and ALT ≤ 1.5 X ULN unless liver metastases are present,&#xD;
                  then AST and ALT ≤ 5.0 X ULN; LDH ≤ 1.5 X ULN; bilirubin ≤ 1.5 mg/dL (0.026&#xD;
                  mmol/L) Corrected calculated calcium ≤ 10 mg/dL (2.5 mmol/L) Calculation = total&#xD;
                  calcium - 0.707 (albumin -3.4)Albumin ≥ 3.0 g/dL (0.45 mmol/L)&#xD;
&#xD;
          -  The subject must not be pregnant or lactating and all subjects (male and female) must&#xD;
             use a contraceptive method deemed acceptable by the investigator while in the study&#xD;
             and for up to two months following completion of therapy.&#xD;
&#xD;
          -  The subject has voluntarily signed and dated an Institutional Review Board&#xD;
             (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will be ineligible for study participation if any of the following criteria are&#xD;
        met:&#xD;
&#xD;
          -  The subject has a history of or currently exhibits Central Nervous System (CNS)&#xD;
             metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of&#xD;
             CNS metastases.&#xD;
&#xD;
          -  The subject is receiving therapeutic anticoagulation therapy. Low dose anticoagulation&#xD;
             (e.g., low dose Coumadin) for catheter prophylaxis will be permitted; PT/PTT must be&#xD;
             within normal limits.&#xD;
&#xD;
          -  The subject has a history of or currently exhibits clinically significant cancer&#xD;
             related events of bleeding (e.g., hemoptysis). The subject has a recent history of&#xD;
             (within 4 weeks of Study Day 1) or currently exhibits other clinically significant&#xD;
             signs of bleeding.&#xD;
&#xD;
          -  The subject exhibits evidence of clinically significant uncontrolled conditions(s)&#xD;
             and/or is considered by the investigator to be unable to tolerate the proposed&#xD;
             treatment or procedures.&#xD;
&#xD;
          -  The subject has history of other previous malignancies within 5 years, with the&#xD;
             exception of: Adequately treated in situ carcinoma of the cervix uteri or Basal or&#xD;
             squamous cell carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rod Humerickhouse, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Associates</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Hematology-Oncology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central indiana Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers Southwest</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Oncology and Hematology Group</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Regional Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Clinic</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>November 17, 2003</study_first_submitted>
  <study_first_submitted_qc>November 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2003</study_first_posted>
  <last_update_submitted>August 13, 2007</last_update_submitted>
  <last_update_submitted_qc>August 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2007</last_update_posted>
  <keyword>Advanced histologically documented renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

